IMMUNOTHERAPY IN HEAD AND NECK CANCER: ADVANCES IN IMMUNE CHECKPOINT INHIBITION AND TARGETED IMMUNOTHERAPIES FOR ENHANCED TREATMENT OUTCOMES

Abstract

Molecular mechanisms involved in head and neck cancers (HNC), predominantly head and neck squamous cell carcinoma (HNSCC), in their heterogeneity manifest clinically through complex interactions involving genetic, epigenetic, and environmental components. Developmental insights from multi-omic analyses have shown the relevance of associated molecular pathways in varying tumor initiation and development, including metastasis. This review describes genetic alterations including TP53, PIK3CA, and CDKN2A plus epigenetic modifications such as aberrant DNA methylation and alterations to histones. Further, the emphasis extended to tumor microenvironment (TME), particularly on the stroma as well as immune and metabolic adaptations supporting tumor expansion and promoting resistance to therapy. Familiarity with these underlying molecular systems is of paramount necessity in developing prospective precision medicine modalities to improve patient outcomes. It is imperative to understand the molecular mechanism of HNSCC for the development of effective treatment strategies. Genetic mutations, epigenetic modification, and interactions in the TME cooperatively drive tumor advancement and therapy resistance. Advances in precision medicine, immunotherapy, and targeted therapies provide hope for bettering patient outcomes. Nevertheless, it is a continuing research field where cancer biology and treatment modalities need further input to face challenges in tumor heterogeneity and therapy resistance. The application of molecular classification methods has backed therapeutic techniques for head and neck squamous cell carcinoma but these treatments have failed to provide effective outcomes. Targeted therapy development becomes challenging because tumors within the same mass develop different genetic along with phenotypic features throughout their structure. Tumors encounter limitations in drug delivery from the blood-brain barrier because of this well-established protective mechanism which hinders systemic drug treatment effectiveness. The major challenge for achieving successful long-term disease control stems from the adaptive genetic and epigenetic changes that lead to treatment resistance.